RxDoctor Payments Data

Edith Arah

Family · Lanham, MDNPI 1437414174

Payments from drug & device makers

$1,082in general payments, 2019–2025

Across 27 payments — averaging $40.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$343
  • Otsuka America Pharmaceutical, Inc.$244
  • Neurocrine Biosciences, Inc.$114
  • Novo Nordisk$99
  • AbbVie$74
  • Axsome Therapeutics, Inc.$61
  • plus $147 from 7 others

What the payments were for

  • Food & beverage$1,082100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,082 in reported general payments places this provider in the 70th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$59,942
Medicare patients
144
Services billed
738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide22$12,337
EliquisApixaban20$12,246
JanuviaSitagliptin Phosphate18$11,159
VascepaIcosapent Ethyl13$4,962
Mesalamine11$3,212
ZenpepLipase/Protease/Amylase12$3,158
Metoprolol Succinate119$2,614
Atorvastatin Calcium140$2,202
CholestyramineCholestyramine (With Sugar)13$2,084
Losartan Potassium164$1,714
Tamsulosin Hcl75$1,558
Amlodipine Besylate219$1,525
Rosuvastatin Calcium72$1,435
Carbamazepine27$1,412
Omeprazole96$1,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$74$12,33722 claims
PfizerEliquis$15$12,24620 claims
MerckJanuvia$32$11,15918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,843 family providers in Maryland.

Other family in Lanham

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →